WeVote
Log In

Bill

Bill

S 9434

Relates to pharmacy benefits where a physician is authorized to dispense certain medications and practices medicine in the oncology setting

2025 Regular Session Introduced by Gustavo Rivera

The bill moves Medicaid oncology drug dispensing from managed care to fee-for-service, with phased planning, 340B pricing considerations, and new reimbursement methods.

REPORTED AND COMMITTED TO FINANCE
0
WeVote Research Nonpartisan
Bill Summary · S 9434

Overview

Bill: S 9434 (New York)
Session: 2025-2026 | Jurisdiction: New York
Title: Relates to pharmacy benefits where a physician is authorized to dispense certain medications and practices medicine in the oncology setting

Purpose: To require the Department of Health (DOH) to remove the pharmacy benefit from the managed care benefit package and provide it under the fee-for-service (FFS) program, with specific transitional timing and implementation safeguards. The change targets pharmacy benefits for certain oncology-related dispensing by physicians or licensed providers practicing medicine in an oncology setting, with a focus on transparency, transition planning, and alignment with 340B drug pricing considerations.

Key Provisions

  • Directive to DOH (pharmacy benefit realignment):
    The bill directs DOH to shift the Medicaid pharmacy benefit from the managed care benefit package to the fee-for-service program. This aligns the dispensing of certain oncology-related medications with FFS administration.

  • Scope of applicability:
    The transition applies when a physician or other licensed health care provider is authorized to dispense medications in accordance with section 6807 of the Education Law and is practicing medicine in an oncology setting, dispensing oncology drugs or drugs related to an approved cancer-treatment course (including symptom-management drugs).

  • Transition timeline and safeguards:

    • The transition cannot begin before April 1, 2023, and may not be implemented until DOH confirms that transition planning is complete, federal approvals are obtained, and necessary preparations are in place (in DOH’s sole discretion).
    • DOH may establish uniform standards, payment policies, and reimbursement methodologies for sites where drugs may be administered or dispensed under the FFS program to ensure orderly transition, continued access, and patient education/support.

  • 340B considerations and reimbursement methodology:

    • When reimbursing entities that are 340B-covered (as defined by 42 U.S.C. § 256b) for drugs that would otherwise be 340B-eligible, DOH must explore all reasonable methods to determine actual acquisition cost and the professional dispensing fee.
    • Beginning in the fiscal year starting April 1, 2023, DOH will review and adjust reimbursement methods for such drugs to (a) reflect actual acquisition costs and (b) professional dispensing fees.
    • No sooner than April 1, 2025, reimbursement shall be determined using a method that the commissioner determines to utilize actual acquisition costs and the professional dispensing fee.

  • Compliance with broader law:
    The amendment modifies Section 1 of Part FFF of Chapter 56 of the Laws of 2020 (as amended by Part C of Chapter 57 of the Laws of 2021) and is intended to operate within existing Medicaid governance and federal law requirements.

Affected Parties

  • Medicaid beneficiaries (needy persons):
    Those receiving oncology-related medications via physician-dispensed routes may transition from managed care to FFS pharmacy benefits, with protections to ensure access and education during the transition.

  • Physicians and licensed healthcare providers (oncology setting):
    Providers authorized to dispense medications under section 6807 Education Law and practicing oncology medication management will be impacted by the change in how dispensing costs and reimbursements are administered.

  • Pharmacies and dispensing sites:
    Sites dispensing drugs under the oncology treatment framework will be subject to new uniform standards, reimbursement methodologies, and potential changes in billing/claims processing.

  • DOH and Medicaid program administrators:
    Responsible for implementing the transition, establishing standards, coordinating with federal requirements, and overseeing reimbursement methodologies, including 340B considerations.

Procedural and Timeline Notes

  • Effective date: Immediate enactment, but key transition actions are governed by timelines noted above (with emphasis on a staged transition starting no earlier than April 1, 2023 and moving toward 2025 for reimbursement method finalization).

  • Federal approvals: Transition contingent on obtaining necessary federal approvals.

  • Transition planning: DOH has discretion to determine when planning is sufficient for transition to proceed.

  • Reimbursement reform milestones:

    • 2023: Explore and implement methodologies to base reimbursements on actual acquisition cost and dispensing fees.
    • 2025: Implement reimbursement method based on actual acquisition cost and professional dispensing fee.

Potential Impact

  • May streamline and standardize how oncology-related medications dispensed by physicians are paid for within Medicaid, potentially improving transparency and consistency in pricing and reimbursement.

  • Could affect cost containment and budgeting for the Medicaid program by aligning pharmacy benefits with FFS payment structures and 340B pricing considerations.

  • The transition emphasizes patient access and education during a shift in how medications are dispensed and reimbursed, aiming to minimize disruptions to care.

  • Administrative burden on DOH and healthcare providers to implement uniform standards and revised reimbursement policies, including coordination with federal programs and 340B entities.

Compiled from official sources — confirm details with the bill’s official record.

Sign in to ask a question.